Corcept Therapeutics (NASDAQ:CORT) Upgraded at Wolfe Research

Wolfe Research upgraded shares of Corcept Therapeutics (NASDAQ:CORT) from an underperform rating to a peer perform rating in a research note issued to investors on Thursday morning, MarketBeat.com reports.

A number of other equities research analysts also recently weighed in on CORT. Truist Financial raised shares of Corcept Therapeutics to a “strong-buy” rating in a research note on Wednesday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Corcept Therapeutics in a research note on Monday, December 29th. Canaccord Genuity Group lifted their target price on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, January 23rd. HC Wainwright cut their price target on Corcept Therapeutics from $67.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Zacks Research lowered Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Corcept Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $77.67.

Corcept Therapeutics Trading Down 2.4%

Shares of CORT opened at $37.60 on Thursday. The stock’s fifty day simple moving average is $37.53 and its 200-day simple moving average is $60.69. The firm has a market capitalization of $4.00 billion, a PE ratio of 45.85 and a beta of 0.29. Corcept Therapeutics has a 12-month low of $28.66 and a 12-month high of $117.33. The company has a quick ratio of 2.85, a current ratio of 2.92 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). The firm had revenue of $202.13 million during the quarter, compared to analyst estimates of $254.94 million. Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.Corcept Therapeutics’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.26 earnings per share. As a group, research analysts predict that Corcept Therapeutics will post 1.36 earnings per share for the current year.

Insider Activity at Corcept Therapeutics

In other Corcept Therapeutics news, insider William Guyer sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $40.87, for a total value of $817,400.00. Following the completion of the sale, the insider owned 1,235 shares of the company’s stock, valued at approximately $50,474.45. This represents a 94.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Joseph K. Belanoff sold 26,198 shares of the stock in a transaction on Wednesday, March 25th. The stock was sold at an average price of $50.07, for a total transaction of $1,311,733.86. Following the completion of the sale, the chief executive officer owned 2,918,326 shares in the company, valued at approximately $146,120,582.82. This trade represents a 0.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 86,198 shares of company stock worth $3,552,769. 20.80% of the stock is currently owned by company insiders.

Institutional Trading of Corcept Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Pathstone Holdings LLC lifted its holdings in Corcept Therapeutics by 0.8% during the third quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock worth $1,497,000 after acquiring an additional 144 shares in the last quarter. Campbell Newman Asset Management Inc. increased its holdings in shares of Corcept Therapeutics by 0.5% in the third quarter. Campbell Newman Asset Management Inc. now owns 35,530 shares of the biotechnology company’s stock worth $2,953,000 after acquiring an additional 170 shares in the last quarter. Clearstead Advisors LLC raised its position in shares of Corcept Therapeutics by 163.6% during the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 193 shares during the period. Gould Capital LLC lifted its holdings in shares of Corcept Therapeutics by 50.0% during the 3rd quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 200 shares in the last quarter. Finally, Advisors Asset Management Inc. lifted its holdings in shares of Corcept Therapeutics by 1.3% during the 2nd quarter. Advisors Asset Management Inc. now owns 18,935 shares of the biotechnology company’s stock valued at $1,390,000 after purchasing an additional 237 shares in the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

More Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: FDA approval of Lifyorli (relacorilant) plus nab‑paclitaxel for platinum‑resistant ovarian cancer is a material commercial catalyst that triggered the earlier sharp rally; approval creates a new revenue pathway and is the primary reason investors re‑rated the stock this week. FDA approval report
• Positive Sentiment: Broker/analyst support: Wolfe Research upgraded CORT (from underperform to peer‑perform) and other brokers (Truist, Canaccord) have issued bullish/strong‑buy views or raised targets, which can sustain buying interest as the market models new sales upside. Wolfe Research upgrade
• Neutral Sentiment: Market structure/volatility: trading halts and large intraday prints accompanied the approval-driven move — expect continued high volume and price swings as investors reprice expectations for launch and uptake. Market reaction coverage
• Neutral Sentiment: Consensus/ratings mix: some outlets show a “moderate buy” brokerage consensus; analysts remain mixed on valuation as the market weighs launch potential vs. prior execution and study data. Broker consensus report
• Negative Sentiment: Legal risk: multiple law firms have filed shareholder alerts and class actions alleging that Corcept misled investors about regulatory issues and patent matters; these suits (and the referenced FDA rejection / federal court patent loss claims) create potential liability, discovery risk and distraction for management. Hagens Berman class‑action alert
• Negative Sentiment: Insider selling: a recent disclosed sale by an insider reduced holdings significantly; while not proof of negative outlook, such sales can weigh on sentiment when paired with litigation headlines. Insider sale filing
• Negative Sentiment: Analyst divergence / forecast cuts: some firms have tempered long‑term estimates or issued cautious notes (e.g., a pessimistic forecast from HC Wainwright in recent coverage), underscoring uncertainty around peak sales and reimbursement. HC Wainwright coverage

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.